Hormone receptor-positive breast cancer
disease diseaseOn this page
Also known as hormone receptor positive breast cancerHR-positive HER2-negative breast cancer
Summary
Hormone receptor-positive breast cancer (MONDO:0700079) is a cancer and 61 clinical trials. Top therapeutic interventions include ribociclib, elacestrant, and abemaciclib. A subtype of progesterone-receptor positive breast cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 61
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | hormone receptor-positive breast cancer |
| Mondo ID | MONDO:0700079 |
| NCIT | C157056 |
| UMLS | C5442556 |
| MedGen | 1825950 |
| Is cancer (heuristic) | yes |
Also known as: hormone receptor positive breast cancer · HR-positive HER2-negative breast cancer
Disease family
This is a subtype of progesterone-receptor positive breast cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › breast carcinoma › breast carcinoma by gene expression profile › progesterone-receptor positive breast cancer › hormone receptor-positive breast cancer
Related subtypes (1): triple-positive breast carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 61.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 22 |
| PHASE1 | 16 |
| Not specified | 14 |
| PHASE1/PHASE2 | 4 |
| PHASE3 | 3 |
| PHASE4 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05452213 | PHASE4 | RECRUITING | Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients |
| NCT07042581 | PHASE4 | RECRUITING | A Study of Revaree Plus in People With Breast Cancer |
| NCT06144944 | PHASE3 | ACTIVE_NOT_RECRUITING | Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer |
| NCT01602380 | PHASE3 | COMPLETED | A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. |
| NCT05503108 | PHASE3 | SUSPENDED | Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer |
| NCT04298086 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study of the Body’s Response to Exercise and a Plant-Based Diet in Overweight Postmenopausal Women With Breast Cancer |
| NCT04569747 | PHASE2 | ACTIVE_NOT_RECRUITING | A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer |
| NCT04872985 | PHASE2 | ACTIVE_NOT_RECRUITING | Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer |
| NCT04997941 | PHASE2 | ACTIVE_NOT_RECRUITING | Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients |
| NCT05020860 | PHASE2 | RECRUITING | Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer |
| NCT05115474 | PHASE2 | RECRUITING | Study of Screening Brain MRIs in Stage IV Breast Cancer |
| NCT05165225 | PHASE2 | ACTIVE_NOT_RECRUITING | Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial |
| NCT05467891 | PHASE2 | RECRUITING | Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer |
| NCT05501704 | PHASE2 | RECRUITING | ETHAN - ET for Male BC |
| NCT05524584 | PHASE2 | RECRUITING | Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer |
| NCT05573126 | PHASE1/PHASE2 | RECRUITING | Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer |
| NCT05608252 | PHASE1/PHASE2 | RECRUITING | VS-6766+Abema+Fulv in Met HR+/HER- BC |
| NCT05766410 | PHASE2 | RECRUITING | A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC |
| NCT06224673 | PHASE2 | NOT_YET_RECRUITING | ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer |
| NCT06263543 | PHASE2 | RECRUITING | Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC |
| NCT06470672 | PHASE2 | NOT_YET_RECRUITING | Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer |
| NCT06518837 | PHASE2 | RECRUITING | Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer |
| NCT06970912 | PHASE2 | RECRUITING | ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer |
| NCT07222215 | PHASE2 | RECRUITING | PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) |
| NCT07366112 | PHASE2 | NOT_YET_RECRUITING | CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment |
| NCT00615524 | PHASE2 | WITHDRAWN | Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer |
| NCT01177397 | PHASE1/PHASE2 | COMPLETED | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma |
| NCT01698918 | PHASE2 | COMPLETED | Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer |
| NCT02675231 | PHASE2 | COMPLETED | A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer |
| NCT02871791 | PHASE1/PHASE2 | COMPLETED | Palbociclib With Everolimus + Exemestane In BC |
| NCT03227328 | PHASE2 | COMPLETED | CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO |
| NCT03401385 | PHASE1 | ACTIVE_NOT_RECRUITING | First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) |
| NCT04706962 | PHASE1 | ACTIVE_NOT_RECRUITING | TH1902 in Patients With Advanced Solid Tumors |
| NCT05868226 | PHASE1 | RECRUITING | PRE-I-SPY Phase I/Ib Oncology Platform Program |
| NCT06120283 | PHASE1 | RECRUITING | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors |
| NCT06253195 | PHASE1 | ACTIVE_NOT_RECRUITING | BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors |
| NCT06257264 | PHASE1 | RECRUITING | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors |
| NCT06545331 | PHASE1 | RECRUITING | Study of XB010 in Subjects With Solid Tumors |
| NCT06570031 | PHASE1 | ACTIVE_NOT_RECRUITING | ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer |
| NCT06678269 | PHASE1 | RECRUITING | A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| RIBOCICLIB | 4 | 4 |
| ELACESTRANT | 4 | 3 |
| ABEMACICLIB | 4 | 1 |
| AMILORIDE | 4 | 1 |
| ANASTROZOLE | 4 | 1 |
| BEVACIZUMAB | 4 | 1 |
| BOSUTINIB | 4 | 1 |
| DEGARELIX | 4 | 1 |
| EXEMESTANE | 4 | 1 |
| FULVESTRANT | 4 | 1 |
| HYALURONIDASE (HUMAN RECOMBINANT) | 4 | 1 |
| PALBOCICLIB | 4 | 1 |
| PAZOPANIB | 4 | 1 |
| SACITUZUMAB GOVITECAN | 4 | 1 |
| TIRZEPATIDE | 4 | 1 |
| TOREMIFENE | 4 | 1 |
| TRASTUZUMAB DERUXTECAN | 4 | 1 |
| TUCATINIB | 4 | 1 |
| ZANIDATAMAB | 4 | 1 |
| PYROTINIB | 3 | 2 |
| ADEBRELIMAB | 3 | 1 |
| AVUTOMETINIB | 3 | 1 |
| DALPICICLIB | 3 | 1 |
| ANVATABART OPADOTIN | 2 | 1 |
| BMS-986310 | 2 | 1 |
| EVORPACEPT | 2 | 1 |
| ONATASERTIB | 2 | 1 |
| SUDOCETAXEL ZENDUSORTIDE | 2 | 1 |
| CHEMBL4068768 | 0 | 1 |
| CHEMBL4171277 | 0 | 1 |
Related Atlas pages
- Drugs: Ribociclib, Elacestrant, Abemaciclib, Amiloride, Anastrozole, Bevacizumab, Bosutinib, Degarelix, Exemestane, Fulvestrant, Hyaluronidase (Human Recombinant), Palbociclib, Pazopanib, Sacituzumab Govitecan, Tirzepatide, Toremifene, Trastuzumab Deruxtecan, Tucatinib, Zanidatamab, Pyrotinib, Adebrelimab, Avutometinib, Dalpiciclib